iShares Biotechnology ETF
858 hedge funds and large institutions have $7.65B invested in iShares Biotechnology ETF in 2021 Q2 according to their latest regulatory filings, with 96 funds opening new positions, 278 increasing their positions, 257 reducing their positions, and 70 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
858
Holders Change
+17
Holders Change %
+2.02%
% of All Funds
14.98%
Holding in Top 10
13
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+62.5%
% of All Funds
0.23%
New
96
Increased
278
Reduced
257
Closed
70
Calls
$497M
Puts
$510M
Net Calls
-$12.6M
Net Calls Change
+$483M
Top Buyers
| 1 |
E
Ergoteles
New York
|
+$82.3M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$81.8M |
| 3 |
TIM
Total Investment Management
Scottsdale,
Arizona
|
+$54.1M |
| 4 |
Twin Tree Management
Dallas,
Texas
|
+$52.3M |
| 5 |
Millennium Management
New York
|
+$44.4M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$441M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$213M |
| 3 |
Goldman Sachs
New York
|
-$209M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$163M |
| 5 |
JPMorgan Chase & Co
New York
|
-$104M |
